SEARCH · PubMed Health

Results for “cold adaptation”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 235 records · Page 13Linked to original sources

PubMedDate not supplied

The development of live attenuated cold-adapted influenza virus vaccine for humans.

A procedure to attenuate live influenza virus of type A and type B was developed using adaptation of the virus to grow at 25 degrees C (cold adaptation; ca). Through a series of stepwise passages, two stable mutants were obtained and designated as 'Master' strains, one for type A influenza virus (A/Ann Arbor/6/60-H2N2) and one for type B influenza virus (B/Ann Arbor/1/66). These mutants were used in genetic reassortment using either the classical method or more recently described reverse genetics to update the relevant surface antigens of the circulating strains of influenza virus. The derivation is based on the concept of 6/2 where 6 signifies the six internal genes of the master strain and 2 refers to the two genes coding for the two surface glycoproteins HA and NA of the circulating influenza virus. The advantages of this vaccine were demonstrated to be (1) proper level of attenuation, (2) non-transmissibility, (3) genetic stability, (4) presence of the ca and ts markers and (5) immunogenicity involving both local and the cell-mediated immune responses. The clinical trials in infants, children, adults and elderly have provided the necessary data for eventual licensing of this vaccine. The ease of administration (intranasal) safety and high efficacy make this vaccine suitable to prevent influenza virus infection in all age groups.

Adaptation, Physiological↗

PubMed2005

Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine.

Optimal conditions are determined for growing cold-adapted reassortant strains of a live influenza vaccine in MDCK cell line cultivated in a fermenter with a serum-free medium and microcarriers. The studied MDCK cell line meet all national and WHO requirements for the finite cell lines used for the production of biological preparations. CA reassortant vaccine strains grown in such conditions which fully preserve its mutations and the mutations lead to amino acid substitution in all genome segments of the studied CA reassortants. Under optimal cultivation conditions, the output of a monovalent live CA influenza vaccine in a 10-l fermenter may reach 100,000 doses.

Adaptation, Physiological↗

PubMedDate not supplied

Biological, genetic and biochemical characterization of a cold-adapted recombinant A/Victoria/3/75 virus and its evaluation in volunteers.

A recombinant virus AA-CR19 was produced that contains RNA segments coding for one polymerase protein, the nucleoprotein and the matrix protein of cold-adapted A/Ann Arbor/6/60, but HA, NA and two other genes coding for polymerase proteins from A/Victoria/3/75. The nonstructural protein gene is probably derived from A/Ann Arbor/6/60, but may contain a spontaneous mutation. Biological characterization of AA-CR19 showed that it possesses the gene(s) responsible for cold-adaptation and temperature-sensitivity of the A/Ann Arbor/6/60 parent. At a dose of 10(7.2) TCID/50. AA-CR19 was found to be immunogenic and attenuated for seronegative volunteers.

Adult↗

PubMedDate not supplied

Attenuation of lentogenic Newcastle disease virus strain B-1 by cold adaptation.

The Hitchner B-1 strain of Newcastle disease virus was plaque-cloned and then serially passaged 36 times in specific-pathogen-free (SPF) chicken embryos incubated at two different temperatures. Virus passaged at a reduced temperature (29 C) was identified as cold-adapted (Ca) and virus passaged at the normal temperature (37 C) was designated non-cold-adapted (non-Ca). The Ca and non-Ca B-1 viruses were compared with the parent B-1 and a commercial B-1 vaccine. In vitro Ca B-1 characteristics included adaptation for more rapid growth at 29 C and the aquisition of temperature sensitivity indicated by substantially reduced growth at 41 C, properties not seen with non-Ca B-1. Embryo mean death times for the Ca virus (140 hr) were longer than for non-Ca B-1 (107 hr) and parent B-1 (121 hr) viruses. The Ca virus retained a rapid (< 2 hr) hemagglutination (HA) elution rate but lost the property of binding the monoclonal antibody AVS-I typical of other B-1 strains. The pathogenicity of the Ca B-1 strain was compared to the non-Ca B-1, parent B-1 strain, and a commercial B-1 strain vaccine in 1-day-old broiler-type chickens. Pathogenicity was evaluated by assessing the severity of respiratory disease signs and the incidence of airsacculitis, perihepatitis, and pericarditis lesions in inoculated chicks. A respiratory disease index was calculated for each B-1 strain based on daily observation scores that determined the presence or absence of disease signs (coughing, rales, labored breathing, death) from 1 to 14 days following intratracheal inoculation with 10(6) 50% egg infective doses of virus per chick. The lower respiratory disease index obtained for the Ca B-1 strain (0.075) indicated it was less pathogenic than the commercial B-1 vaccine (0.296) and the non-Ca (0.478) and parent (0.521) B-1 strains. Ca B-1-infected chicks had only a 5% incidence of air sac lesions, compared to chicks given non-Ca (65%), Hitchner B-1 (65%), or a commercial B-1 vaccine (30%). Immunogenicity tests performed in 1-week-old SPF leghorn chickens demonstrated that Ca B-1 induced complete protection when administered intraocularly as a single entity. However, when Ca B-1 was given in combination with a modified live infectious bronchitis virus vaccine, chickens were only partially protected (60-75%) against Texas GB strain-induced neurotropic velogenic Newcastle disease.

Animals↗

PubMed1986

Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.

Parainfluenza virus type 3 (para 3) was adapted to replicate at 20 degrees C, a nonpermissive temperature for wild-type (wt) para 3. Serial passage at 20 degrees C resulted in the generation of cold-adapted (ca) and temperature-sensitive (ts) mutants. These mutant viruses have been characterized both in vitro and in vivo [Belshe and Hissom (1982): Journal of Medical Virology 10:235-242; Crookshanks and Belshe (1984): Journal of Medical Virology 13:243-249]. We now report the evaluation of three mutants (clone 1150, passaged 12 times in the cold [cp12], clone 1146, passaged 18 times in the cold [cp18], and clone 1328, passaged 45 times in the cold [cp45]) for their ability to protect hamsters from infection by wild-type para 3. Ether-anesthetized male syrian hamsters were intranasally vaccinated with either wt para 3 (clone 127) or one of the ca para 3 mutants and on day 28 post-vaccination; each animal was intranasally challenged with 10(5.0) pfu of wt para 3. On days 1, 2, 3, and 4 post-challenge, 4 to 13 hamsters from each group were sacrificed, and the quantity of para 3 in the nasal turbinates and lungs was determined. Wt virus induced protection from challenge. cp12, cp18, and cp45 reduced the peak titer of wt replication in the lungs by greater than 100-fold, tenfold, and tenfold, respectively. The duration of virus replication was shortened also by intranasal vaccination with the mutants. These data give evidence of an inverse relationship between the degree of protection induced by vaccination with cold-adapted mutants and the number of passages of the virus in the cold.

Administration, Intranasal↗

PubMed1981

Characterization of the temperature sensitive phenotype of the A/Ann Arbor/6/60 cold-adapted virus and its recombinants.

The A/Ann Arbor/6/60 cold-adapted (ca) donor virus had a 38 degrees C shutoff temperature when tested in MDCK tissue culture. ca recombinant viruses bearing all six "internal genes" of the A/Ann Arbor/6/60 ca donor virus and the surface antigens of wild-type virus can manifest a 1,000-fold difference in plaquing efficiency at 38 degrees C. These observations suggest that the A/Ann Arbor/6/60 ca donor genes that specify the temperature sensitive phenotype of the ca recombinants can undergo genetic modification during the production and passage of the recombinants. The NS gene in the ca recombinant virus could be inherited from either parent without influencing the level of temperature sensitivity of the ca recombinant.

Animals↗

PubMed2004

Cold-adapted, live attenuated influenza vaccine.

The recently licensed cold-adapted, live attenuated influenza vaccine (CAIV-T, FluMist, MedImmune Vaccines Inc.) has the potential to enhance control of epidemic influenza. The intranasal vaccine has proven safety and efficacy. Regulatory constraints and cost of CAIV-T have hampered the introduction of the vaccine in the first year. Unwarranted concern about possible transmission of the virus from vaccine recipients to immunocompromised patients limited use in healthcare personnel. The intense influenza A(H3N2) epidemic of 2003-2004 has underscored the necessity of supplementing current efforts to control influenza. Over 120 deaths have been documented in children - the majority of which have been previously healthy. Use of CAIV-T in children will not only decrease the risk of serious disease, but also dampen the spread of the virus in the community and reduce exposure of patients who are at high risk of complications and death.

Adolescent↗

PubMed2005

Cloning, expression, and purification of a recombinant cold-adapted beta-galactosidase from antarctic bacterium Pseudoalteromonas sp. 22b.

The gram-negative antarctic bacterium Pseudoalteromonas sp. 22b, isolated from the alimentary tract of krill Thyssanoessa macrura, synthesizes an intracellular cold-adapted beta-galactosidase. The gene encoding this beta-galactosidase has been PCR amplified, cloned, expressed in Escherichia coli, purified, and characterized. The enzyme is active as a homotetrameric protein, and each monomer consists of 1028 amino acid residues. The enzyme was purified to homogeneity (50% recovery of activity) by using the fast, two-step procedure, including affinity chromatography on PABTG-Sepharose. Enzymatic properties of the recombinant protein are identical to those of native Pseudoalteromonas sp. 22b beta-galactosidase. The enzyme is cold-adapted and at 10 degrees C retains 20% of maximum activity. The purified enzyme displayed maximum activity close to 40 degrees C and at pH of 6.0-8.0. PNPG was its preferred substrate (58% higher activity than against ONPG). The enzyme was particularly thermolabile, losing all activities within 10 min at 50 degrees C. The hydrolysis of lactose in a milk assay revealed that 90% of milk lactose was hydrolyzed during 6 h at 30 degrees C and during 28 h at 15 degrees C. Because of its attributes, the recombinant Pseudoalteromonas sp. 22b beta-galactosidase could be applied at refrigeration temperatures for production of lactose-reduced dairy products.

Amino Acid Sequence↗

PubMedDate not supplied

Cold-adapted and mesophilic brachyurins.

Two different types of brachyurins, termed I and II, have been described in the literature. Within type I there are two subtypes, Ia and Ib. The prototype for the type I brachyurins is Fiddler crab collagenase I. Its cold-adapted analogue from Antarctic krill, termed euphaulysin, shares many of its characteristics. Both enzymes are distinguished by their broad substrate specificity as well as the ability to cleave collagen. The precursor form of euphaulysin has been expressed in Pichia pastoris and processed to its fully active form using cod trypsin. A molecular model of euphaulysin, based on the known crystal structure of crab collagenase I, indicates that the core structure of these enzymes is almost identical. As a cold-adapted enzyme, euphaulysin has a higher catalytic efficiency than crab collagenase I. It is also more sensitive to thermal inactivation and autolysis. Furthermore, euphaulysin has an increased length of several surface loops compared to crab collagenase I. Extended surface loops have been suggested to play a role in the cold activity of some bacterial enzymes. Sensitivity to autolysis is an important factor which contributes to the thermal instability of euphaulysin. Substitution of a highly exposed residue in the 'autolysis loop' of euphaulysin resulted in an increased stability of the enzyme towards thermal inactivation without altering its catalytic efficiency.

Adaptation, Physiological↗

PubMedDate not supplied

Attenuation of avian infectious bronchitis virus by cold-adaptation.

Avian infectious bronchitis virus (IBV) Arkansas-type DPI strain was passaged 10 times in specific-pathogen-free (SPF) chicken embryos incubated at 28 C and 37 C. Virus grown at 28 C acquired cold-adapted (CA) and temperature-sensitive (TS) characteristics based on more-rapid growth at 28 C and a reduced ability to grown at 41 C, respectively, compared with non-cold-adapted (non-CA) virus grown at 37 C. The pathogenicity and immunogenicity were determined for CA and non-CA IBV in 1-day-old SPF chickens following intratracheal inoculation. The percentage of CA IBV-vaccinated chicks exhibiting respiratory disease exceeded 30% on only 1 day postinoculation (PI) (day 5 PI), compared with 8 days (days 2-9 PI) for birds given non-CA IBV. Mortality was 0% for CA IBV-vaccinated chickens and 6% for non-CA virus-vaccinated chickens. Microscopically, both CA and non-CA IBV caused diffuse tracheal deciliation, although mucosal hyperplasia, necrosis, and heterophil infiltration were more severe with non-CA IBV. Virus was reisolated from kidneys of chickens given CA IBV, suggesting the loss of the TS property. The instability of the TS property was confirmed by growth of the reisolated virus at 41 C. Both CA and non-CA viruses induced complete protection against homologous challenge virus infection of the upper respiratory tract.

Animals↗

PubMed2005

Ribosomal cold-adaptation: characterization of the genes encoding the acidic ribosomal P0 and P2 proteins from the Antarctic ciliate Euplotes focardii.

Molecular adaptation at low temperature requires specificities represented mainly by modifications in the gene sequence and consequently in the protein primary structure. To characterize the molecular mechanisms responsible for ribosome cold-adaptation, we compared the ribosomal P0 and P2 genes from the Antarctic ciliate Euplotes focardii with homologous genes from mesophilic organisms, including the ciliates Tetrahymena thermophila and non cold-adapted Euplotes species. This analysis revealed the presence of non synonymous mutations unique to E. focardii. In the P0 protein the mutations produced amino acid substitutions that increased the molecular flexibility that may facilitate a conformational adjustment associated with the interaction with the GTPase center of the large subunit rRNA, and increased the hydrophobicity of the region involved in the interaction with P1/P2 heterodimer, probably to keep associated the ribosomal stalk in the cold. In the P2 protein the mutations produced amino acid substitutions that increased the N-terminus flexibility, which may facilitate interactions with P1 protein in the formation of the heterodimer, and reduced the mobility of the C-terminus, to stabilize the stalk during ribosomal activity. Finally, P proteins appeared to be valid markers for investigating the phylogenetic origin of early eukaryotes.

Adaptation, Physiological↗

PubMedDate not supplied

Cold-adapted strain of avian pneumovirus as a vaccine in one-day-old turkeys and the effect of inoculation routes.

To determine the optimum route of vaccination, we inoculated 1-day-old turkeys with a cold-adapted strain of avian pneumovirus (APV) by oculonasal, oral, or aerosol route. Another two groups served as nonvaccinated-challenged and nonvaccinated-nonchallenged groups. Birds in all vaccinated and nonvaccinated-challenged groups were challenged with virulent APV 3 wk postvaccination. After challenge, no vaccinated bird developed clinical signs or virus shedding, whereas nonvaccinated-challenged birds developed clinical signs (clinical score = 11.2/bird) and shed virus from their choanal cleft. Birds in all three vaccinated groups seroconverted at 3 wk postvaccination. The nonvaccinated-nonchallenged group remained free of clinical signs and virus shedding and did not develop APV antibodies throughout the course of the study. These results suggest that this cold-adapted strain of APV is safe and effective in 1-day-old turkeys when given by any of the three routes.

Adaptation, Physiological↗

PubMed2003

Hydrocarbon degradation and enzyme activities of cold-adapted bacteria and yeasts.

The potential of 89 culturable cold-adapted isolates from uncontaminated habitats, including 61 bacterial and 28 yeast strains, to utilize representative fractions of petroleum hydrocarbons (n-alkanes, monoaromatic and polycyclic aromatic hydrocarbons) for growth and to produce various enzymes at 10 degrees C was investigated. The efficiency of bacterial and yeast strains was compared. The growth temperature range of the yeast strains was significantly smaller than that of the bacterial strains. Sixty percent of the yeasts but only 8% of the bacteria could be classified as true psychrophiles, showing no growth above 20 degrees C. A high percentage (89%) of the yeast strains showed lipase activity. More than one-third of the 61 bacterial strains produced amylase, beta-lactamase, beta-galactosidase or lipase; more than two-thirds were protease producers. Only 6% of the bacterial strains but 79% of the yeast strains utilized n-hexadecane for growth; 13% of the bacterial strains and 21-32% of the yeast strains utilized phenol, phenanthrene or anthracene for growth. Only four yeast strains but none of the bacterial strains could grow with all hydrocarbons tested. The biodegradation of phenol was investigated in fed-batch cultures at 10 degrees C. Three yeast strains degraded phenol concentrations as high as 10 mM (one strain) or 12.5 mM (two strains). Of eight bacterial strains, two strains degraded up to 10 mM phenol. The optimum temperature for phenol degradation was 20 degrees C for all eight bacterial strains and for two yeast strains. Biodegradation by five yeast strains was optimal at 10 degrees C and faster at 1 degrees C than at 20 degrees C. All phenol-degrading strains produced catechol 1,2 dioxygenase activity.

Adaptation, Physiological↗

PubMed1977

Comparative studies of wild-type and 'cold-mutant' (temperature sensitive) influenza viruses: geneology of the matrix (M) and non-structural (NS) proteins in recombinant cold-adapted H3N2 viruses.

The matrix (M) protein of the H2N2 virus A/Ann Arbor/6/60 may be distinguished from M protein of several H3N2 viruses and A/New Jersey/76 (HSWINI) by SDS acrylamide gel electrophoresis using a discontinuous buffer system. The smallest RNA (RNA 8) of the A/Ann Arbor/6/60 virus may be distinguished from RNA 8 of several H3N2 viruses by acrylamide gel electrophoresis in 3% or 3-6% gels in the absence of urea, if electrophoresis is done at 30 to 36 degrees C or 20 degrees C respectively. Ten clones of conditionally-lethal temperature-sensitive (ts) mutants were studied, which derived their cold-adaption and ts genes from mutant A/Ann Arbor/6/60, and their haemagglutinin from the H3N2 virus A/Scotland/840/74. Each clone was found to derive its M protein from A/Ann Arbor/6/60 mutant, and its RNA 8 from A/Scotland/840/74. The only assignment of genes 7 and 8 consistent with these findings for the recombinants is that in each parent virus (and in the recombinants) gene 7 codes for M protein, and gene 8 for NS protein. Furthermore, it may be concluded from the results that the biologically important ts lesions in the A/Ann Arbor/6/60 mutant parent are not present in the NS gene. In addition to the recombinants of A/Ann Arbor/6/60 and A/Scotland/840/74, five independent ts/cold-adapted recombinants of A/Ann Arbor/6/60 mutant with H3N2 and HSWINI wild-type viruses were examined, and all were found to contain the M protein of the A/Ann Arbor/6/60 mutant parent. This is suggestive that M protein may be at least partially responsible for the cold-adaptation and/or ts properties of the A/Ann Arbor/6/60 mutant and the recombinants.

Adaptation, Biological↗

PubMed1997

Psychrophilic enzymes: molecular basis of cold adaptation.

Psychrophilic organisms have successfully colonized polar and alpine regions and are able to grow efficiently at sub-zero temperatures. At the enzymatic level, such organisms have to cope with the reduction of chemical reaction rates induced by low temperatures in order to maintain adequate metabolic fluxes. Thermal compensation in cold-adapted enzymes is reached through improved turnover number and catalytic efficiency. This optimization of the catalytic parameters can originate from a highly flexible structure which provides enhanced abilities to undergo conformational changes during catalysis. Thermal instability of cold-adapted enzymes is therefore regarded as a consequence of their conformational flexibility. A survey of the psychrophilic enzymes studied so far reveals only minor alterations of the primary structure when compared to mesophilic or thermophilic homologues. However, all known structural factors and weak interactions involved in protein stability are either reduced in number or modified in order to increase their flexibility.

Adaptation, Biological↗

PubMed1995

Distribution of acetylated tubulin in cultured cells and tissues from the Atlantic cod (Gadus morhua). Role of acetylation in cold adaptation and drug stability.

The Atlantic cod (Gadus morhua) is a poikilothermic animal living at temperatures between 2-15 degrees C. Isolated cod brain tubulin is, in contrast to mammalian brain tubulin, posttranslationally modified by acetylation to a high extent. To investigate the role of acetylation in cold adaptation, microtubules were isolated by a taxol-dependent procedure from different organs of the cod, and cells from different tissues were cultured. All cells from skin and brain were able to grow between 4 degrees C and room temperature. Microtubules in the cultured cells were sometimes severed near the periphery of the cells. Microtubules in brain cells were in general more stable to vinblastine and colchicine, when compared to skin cells. Acetylated microtubules were found only in brain cells, in peripheral nerves on scales and in nerves of the intestinal tract and in microtubules isolated from neuronal tissue. Our results show that acetylated microtubules are found both in the central and peripheral nervous system, but that there is no correlation between acetylation and cold-adaptation.

Acetylation↗

PubMed1982

[Mechanisms of the effect of cold adaptation on the resistance to hyperoxia].

Hyperoxia after 3-day exposure at 2-4 degrees C induces more obvious disturbance of metabolites in rats than each of the factors separately. Along with decreased arginase activity in the brain and liver by 23 and 32% resp., the urine content decreases as well by 36 and 37% resp. Resistance of these animals against hyperoxia is reduced. But a preliminary 45-day cold-adaptation at 2-4 degrees C leads to a considerable activation of liver arginase and to increased content of urine in brain and liver by 32 and 30%, resp. The activation of arginase--urine system preserves under hyperoxia: the cold-adapted animals prove more resistant against hyperoxia effect. The above dynamic changes seem to be one of possible unspecific biochemical mechanisms of increasing the organism resistance against effects of extreme factors.

Adaptation, Physiological↗

PubMed1998

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

BACKGROUND: Influenzavirus vaccine is used infrequently in healthy children, even though the rates of influenza in this group are high. We conducted a multicenter, double-blind, placebo-controlled trial of a live attenuated, cold-adapted, trivalent influenzavirus vaccine in children 15 to 71 months old. METHODS: Two hundred eighty-eight children were assigned to receive one dose of vaccine or placebo given by intranasal spray, and 1314 were assigned to receive two doses approximately 60 days apart. The strains included in the vaccine were antigenically equivalent to those in the inactivated influenzavirus vaccine in use at the time. The subjects were monitored with viral cultures for influenza during the subsequent influenza season. A case of influenza was defined as an illness associated with the isolation of wild-type influenzavirus from respiratory secretions. RESULTS: The intranasal vaccine was accepted and well tolerated. Among children who were initially seronegative, antibody titers increased by a factor of four in 61 to 96 percent, depending on the influenza strain. Culture-positive influenza was significantly less common in the vaccine group (14 cases among 1070 subjects) than the placebo group (95 cases among 532 subjects). The vaccine efficacy was 93 percent (95 percent confidence interval, 88 to 96 percent) against culture-confirmed influenza. Both the one-dose regimen (89 percent efficacy) and the two-dose regimen (94 percent efficacy) were efficacious, and the vaccine was efficacious against both strains of influenza circulating in 1996-1997, A(H3N2) and B. The vaccinated children had significantly fewer febrile illnesses, including 30 percent fewer episodes of febrile otitis media (95 percent confidence interval, 18 to 45 percent; P<0.001). CONCLUSIONS: A live attenuated, cold-adapted influenzavirus vaccine was safe, immunogenic, and effective against influenza A(H3N2) and B in healthy children.

Administration, Intranasal↗